COMPANY
Novo Nordisk Inc
Novo Nordisk Inc: warning letter recipient, recalling firm for Liraglutide, Semaglutide, Tirzepatide, Glucagon, Insulin degludec, as stated by public registers.
Also written as: Novo Nordisk Inc..
WARNING LETTER RECIPIENT
Received an FDA warning letter naming the peptide.
| Liraglutide | False & Misleading Claims/Misbranded, 2025-09-09 Regulator FDA warning letters |
|---|---|
| Liraglutide | Postmarketing Adverse Drug Experience Reporting Requirements, 2026-03-05 Regulator FDA warning letters |
| Semaglutide | False & Misleading Claims/Misbranded, 2025-09-09 Regulator FDA warning letters |
| Semaglutide | Postmarketing Adverse Drug Experience Reporting Requirements, 2026-03-05 Regulator FDA warning letters |
| Tirzepatide | False & Misleading Claims/Misbranded, 2025-09-09 Regulator FDA warning letters |
RECALLING FIRM
Recalled a product naming the peptide (FDA enforcement report).
| Glucagon | Class I recall, Terminated, 2016-12-28 Regulator openFDA |
|---|---|
| Insulin degludec | Class I recall, Terminated, 2021-04-21 Regulator openFDA |
| Liraglutide | Class II recall, Terminated, 2021-04-21 Regulator openFDA |
| Semaglutide | Class II recall, Ongoing, 2026-01-07 Regulator openFDA |
| Semaglutide | Class II recall, Terminated, 2021-04-21 Regulator openFDA |
What a register states, not an endorsement or an accusation by this site. All companies.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.